Landmark Study Published in the Journal of the American Medical Association (JAMA) Surgery Validates Bridge to Life's VitaSmart™ HOPE Perfusion System as a Superior Organ Preservation Technology

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

BTL-VitaSmart-study

More Like This

PR Newswire associated0

Bridge to Life Ltd. Achieves Global Milestone Using Hypothermic Oxygenated Perfusion (HOPE) and VitaSmart™ System

PR Newswire associated0

Bridge to Life Presents New ILTS 2026 Data Showing VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) Expands Use of Marginal Donor Livers and Preserves Mitochondrial Function for Real-Time Viability Assessment

PR Newswire associated0

Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation

PR Newswire associated0

Bridge to Life Acquires VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.

PR Newswire associated0

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

PR Newswire associated0

First-Ever Multicenter Study of Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in Pediatric Liver Transplants Confirms Safety and Favorable Outcomes

PR Newswire associated0

Bridge to Life™ Unveils Groundbreaking 12-Month Clinical Trial Data on HOPE at World Transplant Congress 2025

PR Newswire associated0

First-Ever Comparative Study of Hypothermic Oxygenated Machine Perfusion (HOPE) with Normothermic Machine Perfusion (NMP) in Liver Transplantation Shows Better Outcomes With HOPE